Ten nM thapsigargin (a SERCA inhibitor), 1 [micro]M atropine (a
muscarinic receptor blocker) and 100 [micro]M L-NAME (a NO synthase inhibitor) and 500 uM DECC were used to investigate the mechanisms of DECC action.
Stereoselectivity of satropane, a novel tropane analog, on iris
muscarinic receptor activation and intraocular hypotension.
Muscarinic receptors as binding sites for [[sup.3]H]QNB or [[sup.3]H]NMS.
Baseline and frequent monitoring should be completed of the patient's vital signs, urinary output, bowel sounds, and cardiac rhythm to determine therapeutic effect and signs of excessive anticholinergic stimulation brought about by
muscarinic receptor blockade.
Characterization of
muscarinic receptors in the rat nucleus tractus solitarius.
Second, the blockade of other
muscarinic receptor subtypes leads to adverse effects of antimuscarinic therapy.
Activating the worms'
muscarinic receptors triggered the identical behavior and biochemical response that starvation did, showing that the receptor controls the muscles' response to hunger.
Scopolamine is believed to bind well to all types of
muscarinic receptors. In their study of 16 agents, Wood and Graybiel found that oral scopolamine was the most effective single agent in preventing vertigo.
Compared with older anticholinergics approved for OAB, solifenacin is a more selective
muscarinic receptor blocker, as is trospium chloride, Richard Bercik, M.D., director of the division of urogynecology and reconstructive surgery at Yale University, New Haven, said in an interview.
As with other anticholinergics, tiotropium causes bronchodilation by blocking the
muscarinic receptors in the parasympathetic nervous system.
Upon release into the synaptic cleft, acetylcholine diffuses to its site of action to combine with nicotinic or
muscarinic receptors on the post-synaptic cell or pre-junctional receptors on the nerve terminal itself to auto-regulate further release.
KarXT, a proprietary oral modulator of
muscarinic receptors, is the Company's lead product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate
muscarinic receptors in the central nervous system (CNS).
